Arndt Vogel, Head of the Center for Personalized Medicine, MHH at Medical University of Hanover, shared a post on X:
“Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in BCLC A HCC and high risk of recurrence
- 43 pts, NIVOLEP trial
- ORR 25% after Nivo
- 2yrs OS rate 75%
Not sure whether there is a future for IRI in HCC, but interesting data.”
Title: Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with BCLC a hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial)
Authors: Pierre Nahon, Marianne Ziol, Long Pan, Jean-Jacques Portal, Frederic Oberti, Christophe Aube, Jean-Frederic Blanc, Hervé Trillaud, Philippe Merle, Agnès Rode, Eric Assenat, Boris Guiu, Marie Lequoy, François Cornelis, Mohamed Bouattour, Zohra Talib, Annick Tibi, Qinghe Zeng, Yasmine Bouda, Nathalie Ganne-Carrié, Olivier Sutter, Angela Sutton, Erwan Guyot, Nathalie Barget, Jessica Zucman-Rossi, Claudia Campani, Jessica Bamba-Funck, Julien Calderaro, Jean-Charles Nault, Eric Vicaut, Olivier Seror
Read the Full Article.
Other articles featuring Arndt Vogel on OncoDaily.